Novonesis
At Novonesis, we believe solutions rooted in biology are key to tackling the challenges our world faces. Enzymes, functional proteins and microorganisms are our planet's tiniest, yet mightiest agents of change. When we leverage their power with science, we create biosolutions that transform the way we all produce, consume and live. Today, we are 10,000 people worldwide whose expertise spans …
Profile
- Industry
- Energy, Feed, Food ingredients, Industrial chemistry, Post-harvest & processing
- Topics
- Enzymes & biocatalysis
- Role
- Producer — “…n Denmark that develops and manufactures enzymes, microbes, and other biological solutions for over 30 industr…”
- Why it is bioeconomy
- Novonesis is a leading global biosolutions company formed by the merger of Novozymes and Chr. Hansen, specializing in the development and production of enzymes and microbial solutions for various industries.
Bio-solutions it supplies 1
| D2E2 | Detergent enzymes for low-temperature washing instead of phosphates, extra surfactant and hot washing |
Verified product links: Denimax → T02; Lipozyme interesterification replaces → FI08; reduces greenhouse gas emissions by up to 22% → FI08; Lecitase Ultra → FI08; Termamyl → FI10; Eversa → EN03; Lipura → I02; enzymatic esterification process → I02; Innova → EN02; Fiberex → EN02; Fortiva → EN02; JumpStart → A36; 80 million acres → A35, A36; replace a significant portion of chemical surfactants → I07; over half of the world's population → I07;
What they offer
This company does not publish its products or services — we find out through an introduction.
Business model · role model
Novonesis is a global biotechnology company that produces enzymes, cultures, and probiotics for a wide range of industries, including food and beverages, human health, household care, and agriculture. It sells these performance biosolutions to business customers globally, earning revenue through direct sales and distribution channels. The company creates value by leveraging its proprietary microbial strain library and fermentation capabilities to provide solutions that improve product performance, sustainability, and efficiency for its clients.
| Biosolutions 2024 Novonesis operates through two main business segments: Food & Health Biosolutions and Planetary Health Biosolutions. “Our business is split into two divisions: Food & Health Biosolutions and Planetary Health Biosolutions.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 Novonesis reported pro forma sales of EUR 3,945.5 million in 2024. “Novonesis realized pro forma sales of EUR 3,945.5 million in 2024, of which Food & Health Biosolutions represented 45%, while Planetary Health Biosolutions represented 55%.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 The company achieved a pro forma adjusted EBITDA margin of 36.1% in 2024. “Pro forma adjusted EBITDA was EUR 1,423.4 mil lion in 2024, representing a pro forma adjusted EBITDA margin of 36.1%” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 Novonesis reinvests approximately 11% of its sales into research and development. “In 2024, we reinvested close to 11% of our sales into research and development (R&D), as innovation is a critical long-term enabler to deliver impactful customer solutions.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 The company has accumulated nearly 10,000 patents. “With an annual investment of currently around EUR 400 million in research and development, we have accumulated nearly 10,000 patents, and we con sistently introduce a significant number of new products each year.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 The statutory merger between Novozymes A/S and Chr. Hansen Holding A/S was completed on January 29, 2024. “On January 29, 2024, the final regulatory approvals were obtained and the final registration of the statutory merger between Novozymes A/S (“Novozymes”) and Chr. Hansen Holding A/S (“Chr. Hansen”) was successfully …” | regnskaber.cvrapi.dk weak (company, news, market research, other) |
| Denimax® family The Denimax family of products replaces pumice stones in denim abrasion, reducing environmental impact and costs. “A small dose of this product can replace several kilograms of stones.” | www.novonesis.com weak (company, news, market research, other) |
| Eversa® Advance Eversa® Advance replaces acid esterification in biodiesel feedstock pretreatment, improving efficiency and sustainability. “With Eversa® Advance, biodiesel producers can replace acids with enzymes, ensuring a smooth plant throughput, reduced need for maintenance and methanol rectification, and a more sustainable process.” | www.novonesis.com weak (company, news, market research, other) |
| uhde® enzymatic esterification The enzymatic esterification process replaces traditional chemical catalysts like inorganic acids or metal-based catalysts in ester production. “The new enzymatic esterification process developed by thyssenkrupp Uhde leverages Novonesis’ bespoke enzymes as catalysts, replacing traditional chemical catalysts such as inorganic acids or metal-based catalysts.” | www.thyssenkrupp-uhde.com weak (company, news, market research, other) |
| Lipura® Split The enzymatic fat-splitting process using Lipura® Split replaces conventional thermal fat-splitting towers. “To address these challenges, Novonesis and thyssenkrupp Uhde are jointly launching an enzymatic fat-splitting process using the Novonesis Lipura® Split enzyme.” | www.novonesis.com weak (company, news, market research, other) |
| Multi-enzyme solutions 2014 Enzymes are used to replace phosphates (STPP) in laundry detergents to reduce environmental impact while maintaining cleaning performance. “The combination of modifying detergent compositions and using multienzyme solutions enables the detergent manufacturers to replace phosphates without compromising the cleaning performance.” | www.slideserve.com weak (company, news, market research, other) |
| Enzyme-based detergents 2025 Enzymes allow for washing at lower temperatures, which significantly reduces the energy consumption and carbon footprint associated with heating water. “One of the most significant advantages of using enzymes in detergents is their ability to catalyze biological reactions at lower temperatures.” | ml-eu.globenewswire.com weak (company, news, market research, other) |
Status
Recent news 5
Found by automated search; summaries are machine-written in English. The headline names the company or the summary is about it — check the source before relying on it.
- 2026-09-22 Novonesis stock gains support from DKK 1 billion buyback ad-hoc-news.deNovonesis is supported by a large DKK 1 billion buyback, helping underpin a stock near the upper end of its 52-week range at around DKK 430.50, while brokers still see upside driven by earnings growth and margins despite the buyback.
- 2026-09-01 Efterspørgsel på mælkeprodukter driver vækst hos Novonesis | avisendanmark.dk avisendanmark.dkNovonesis is experiencing growth driven by rising demand for fresh, high-protein dairy products. The company is the merged entity of Chr. Hansen and Novozymes, headquartered in Lyngby.
- 2026-08-20 Novonesis beats expectations and raises guidance - Ritzau - Danish News in English powered by The Copenhagen Post danishnews.cphpost.dkNovonesis exceeded expectations in Q2, posting 1.116 billion euros in revenue and a quarterly profit of 179.4 million euros. The company raised its full-year organic revenue growth outlook to 7–8% (from 5–7%), driven by strong demand for biosolutions, especially in the food and …
- 2026-08-19 H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook | Novonesis novonesis.comNovonesis posted strong H1 2026 results with 8% organic sales growth (9% in Q2) and an EBITDA margin of 37.7%, and raised its full-year outlook to 7–8% organic growth with margins at the high end of 37–38%, plus an inaugural €1 billion multi-year share buyback and progress on …
- 2026-08-04 Novonesis vokser, mens rivaler kæmper: Her er direktørs forklaring borsen.dkNovonesis is growing faster than expected, driven by strong sales growth in several new markets, despite skepticism and weaker results from competitors.
Seen at forums
- Events
- BIO Innovations North America World Bio Markets
- Years
- 2021–2026
Listed in the programme or participant lists of these events; this is not an endorsement or a ranking. Data sources and method →
Network: owners, partners, peers
Similar companies
AB Enzymes · c-LEcta GmbH · Solyve · BiCT srl - Biological and Chemical Technologies · Biocatalysts Ltd · enginzyme · SternEnzym · Enzymicals AG
Company facts
Registry identifiers
- Novozymes A/S reg. no.: 10007127
Funding
- Latest round: Debt financing · 2026-03-01
From automated research (company websites, filings, a commercial company index); not checked by hand. Registry identifiers: confirm in the official registry.
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member